ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 420

Loss-of-Co-Homozygosity Mapping and Exome Sequencing of a Syrian Pedigree Identified the Candidate Causal Mutation Associated with Rheumatoid Arthritis

Yukinori Okada1, Namrata Gupta2, Daniel Mirel2, Stacey Gabriel2, Thurayya Arayssi3, Faten Mouassess4, Walid AL Achkar4, Layla Kazkaz5 and Robert M. Plenge6, 1Division of Rheumatology, Immunology, and Allergy, 1.Brigham and Women's Hospital, Harvard Medical School, 2.Program in Medical and Population Genetics, Broad Institute, Boston, MA, 2The Broad Institute, Cambridge, MA, 3Internal Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar, 4Human Genetics, Molecular Biology and Biotechnology, Damascus, Syria, 5Tishreen Hospital and the Syrian Association for Rheumatology, Damascus, Syria, Damascus, Syria, 6Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: genomics and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Although there are >50 rheumatoid arthritis (RA) risk loci that contain common variants, there are no known genomic loci that harbor rare mutations that influence RA risk in a Mendelian fashion. Here, we perform whole exome sequencing to search for rare, causal mutations in a 4-generation, 48-person consanguineous Syrian pedigree in which 8 individuals were affected with seropositive rheumatoid arthritis (RA). 

Methods:   We performed GWAS genotyping on 16 family members (affected and unaffected) and genome-wide exome sequencing in 4 CCP+ RA cases. To search for rare causal mutations, we developed a novel non-parametric linkage analysis we term “Loss-of-co-Homozygosity” (LOcH) mapping that extends homozygosity mapping to include any type of inheritance mode. The fundamental principal underlying LOcH is that a disease-causing mutation in a pedigree resides on a single ancestral haplotype, and that affected individuals will carry at least one copy of the mutation – but are never homozygous for the non-mutated allele. We used LOcH mapping to search the genome for regional stretches that lose one or both homozygous genotypes (i.e., lose “co-homozygosity”) in affected cases, which serve as candidate regions harboring rare causal mutations. Within the detected LOcH stretches, we performed imputation of mutations identified by exome sequencing.  We evaluated the presence of the LOcH stretches in other non-exome-sequenced subjects, and calculated a P-value for association with case-control status using Fisher’s exact test.

Results:   Using GWAS data and LOcH mapping, we identified ~12% of the genome in which the same ancestral haplotype was shared among all RA cases. Within these regions, we identified 13 nonsense or missense mutations shared among all cases but not observed in dbSNP, the 1000 Genomes Project, or the Exome Sequencing Project. We imputed these 13 candidate mutations in all unaffected family members, and found that 1 mutation preferentially segregated in cases compared to controls: all 4 RA cases inherited this mutation, but only 3/12 controls were heterozygous for the mutation (P = 0.02). The mutated gene is phospholipase B1 (PLB1), which has been implicated in human epidermal barrier function but not yet implicated in RA or other autoimmune diseases.

Conclusion:   While additional investigation of this mutation is required to confirm the association with risk of RA, the approach highlights a novel method of statistical analysis of genome-wide sequence data.


Disclosure:

Y. Okada,
None;

N. Gupta,
None;

D. Mirel,
None;

S. Gabriel,
None;

T. Arayssi,
None;

F. Mouassess,
None;

W. AL Achkar,
None;

L. Kazkaz,
None;

R. M. Plenge,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/loss-of-co-homozygosity-mapping-and-exome-sequencing-of-a-syrian-pedigree-identified-the-candidate-causal-mutation-associated-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology